Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheap blood count ratios eyed as window into Myeloma's inflammatory grip

NCT ID NCT07823959

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Multiple myeloma is a blood cancer in which abnormal plasma cells build up in bone marrow, and inflammation may shape how the disease behaves. Researchers at Assiut University plan to study 60 people newly diagnosed with myeloma before any anti-myeloma treatment begins. They will check whether simple inflammation ratios from routine complete blood counts, such as the neutrophil-to-lymphocyte ratio, line up with disease severity measures like bone marrow plasma cell percentage and with the surface features of the cancer cells. The goal is to see whether these inexpensive markers could one day help doctors assess myeloma without costly tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the ratios track with disease severity, doctors could one day use a routine blood count to help gauge how advanced a myeloma case is without extra tests.
What could go wrong
This is a small, single-region observational study of 60 people, so any link it finds may not hold in other patients or prove that inflammation drives the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with newly diagnosed Multiple Myeloma presenting to the Clinical Pathology and Oncology Departments at Assiut University Hospital and South Egypt Cancer Institute, prior to the initiation of anti-myeloma therapy.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed Multiple Myeloma patients, evaluated prior to the initiation of anti-myeloma therapy * Both sexes, with no age restriction Exclusion Criteria: * Prior receipt of anti-myeloma treatment * Concurrent active malignancies or other hematological disorders * Presence of acute or chronic inflammatory or infectious conditions that may influence systemic inflammatory indices * Concomitant use of medications that significantly alter inflammatory or hematological parameters

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.